Fidelity Investments
STAB

Fidelity Investments’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Fidelity Investments’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-46
Closed – – 5155
2021
Q3 		$0 Sell
46
-54
-54% -$205 ﹤0.01% 5272
2021
Q2 		$1K Buy
+100
New +$538 ﹤0.01% 4149

Other funds holding STAB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments's STAB Position: Q4 2021 in Review

Fidelity Investments sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q4 2021, closing a stake of 46 shares.

Fidelity Investments first reported a position in STAB in Q2 2021 and held it in 2 quarters. The position peaked at $1K in Q2 2021. 29 funds tracked by Wall St. Rank hold STAB as of Q4 2021.

  • Fidelity Investments reported no remaining Statera Biopharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Fidelity Investments sold 46 Statera Biopharma, Inc. Common Stock shares in Q4 2021.
  • Fidelity Investments first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Fidelity Investments's Statera Biopharma, Inc. Common Stock position peaked at $1K in Q2 2021.
  • 29 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q4 2021.

Based on Fidelity Investments's 13F filing for Q4 2021, filed 14 Feb 2022.